Business Context and Reporting Period
This Form 8-K is a current report filed by Histogenics Corporation (not Ocugen, Inc.) on March 5, 2019, regarding events occurring on February 27, 2019. The registrant is a Delaware corporation and an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
- Board Resignation: John Johnson resigned as a member of the Board of Directors and all committees effective February 27, 2019, to devote full-time efforts to other commitments.
- Reason for Departure: The resignation was not due to any disagreement with the Company's operations, financials, policies, or procedures.
- Board Size Reduction: The number of directors was reduced from seven to six effective February 27, 2019.
- Committee Appointments:
- Mr. Baltzell was appointed Chairman of the Compensation Committee.
- Susan Washer was appointed as a member of the Audit Committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a standard disclosure of officer and director changes.
Investor Verification Checklist
- Verify the current composition of the Board of Directors and committee memberships.
- Confirm the independence status of Susan Washer regarding the Audit Committee.
- Review subsequent filings to ensure no undisclosed disagreements arose regarding the resignation.